Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Izervay
Pharma
Study says top launches were for drugs for untreated diseases
Drugs for untreated diseases and those launched by experienced companies have the best chance to achieve quick uptake, according to a Trinity report.
Kevin Dunleavy
Nov 6, 2024 9:55am
Astellas pulls application for Izervay after talks with CHMP
Oct 28, 2024 11:07am
Astellas cruises into first DTC campaign for GA med Izervay
Sep 30, 2024 4:00pm
Apellis stock price slid 10% despite 'robust' growth of Syfovre
May 8, 2024 11:30am
Apellis working through continued challenges with Syfovre launch
Feb 28, 2024 11:53am
Astellas raises expectations for Padcev, lowers them for Veozah
Feb 5, 2024 10:57am
